Why the study?
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
Population
100 patients with Dilated Cardiomyopathy (DCM), mean age 47.7 years, mean NYHA class 2.17, mean LVEF 27.3%
Comparison
Trimetazidine 20 mg three times daily for 3-6… vs Conventional therapy
Design
RCT, randomized
Follow-up
3-6 months
Authors
Loading...
Supports adjunctive trimetazidine in dilated cardiomyopathy; extends RCT evidence for metabolic modulation in HFrEF.
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
Trimetazidine added to conventional therapy significantly improves functional capacity, left ventricular ejection fraction, and BNP levels in patients with dilated cardiomyopathy.
Kapoor et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: